Summary
Ciclosporin, an immunosuppressant, is metabolized by the liver cytochrome P450 system. Changes in the pattern of its metabolites in blood and urine in patients with disturbed liver function have been studied.
Forty seven kidney graft patients receiving 2.9 mg/kg/d ciclosporin b.i.d., and no additional medication that would interfere with ciclosporin metabolism, were allocated to three groups according to liver function: I with normal liver function (n=19), II with elevated liver enzyme activity or bilirubin concentration in serum (n=20), and III with cholestasis (n=8). Ciclosporin and 17 metabolites were determined in blood and 24 h-urine.
In blood the trough concentrations of metabolites M19 and M1A were significantly higher in group III than in groups I and II. The total quantity of metabolites excreted in 24 h-urine was significantly different for H230, M4N69 and M1A (group III>I=II). Renal excretion of the daily dose of ciclosporin in patients in group I was 2.7%, group II 3% and group III 5.7%. In group III compared to group I the ciclosporin metabolite pattern was shifted to a relatively higher concentration of M19 in blood and of H 230, M19 and M1A in urine.
Since high ciclosporin metabolite concentrations appear to be associated with nephrotoxicity, the metabolite pattern in patients with impaired liver function should be monitored.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bleck JS, Schlitt HJ, Christians U, Thiesemann C, Strohmeyer S, Schottmann R, Kohlhaw K, Wonigeit K, Sewing KF (1989) Urinary excretion of ciclosporin and 17 of its metabolites in renal allograft recipients. Pharmacology 39: 160–164
Bowers LD, Norman DD, Henion JD (1988) Isolation and characterization of cyclosporine metabolites using HPLC and tandem mass spectrometry. Transplant Proc 20: 597–601
Christians U, Sewing KF (1989) Blood sample preparation. In: Zech K, Frei RW (eds) Selective sample handling and detection in high-performance liquid chromatography, Part. Elsevier, Amsterdam, pp 82–132
Christians U, Schlitt HJ, Bleck JS, Schiebel HM, Kownatzki R, Maurer G, Strohmeyer S, Schottmann R, Wonigeit K, Pichlmayr R, Sewing KF (1988a) Measurement of ciclosporin and 18 metabolites in blood, bile and urine by high-performance liquid chromatography (HPLC). Transplant Proc 20: 609–613
Christians U, Zimmer KO, Wonigeit K, Maurer G, Sewing KF (1988b) Liquid chromatographic measurement of cyclosporin A and its metabolites in blood, bile, and urine. Clin Chem 34: 34–39
Christians U, Zimmer KO, Wonigeit K, Sewing KF (1987) Measurement of cyclosporin A and four of its metabolites in whole blood by high-performance liquid chromatography. J Chromatogr 413: 121–129
Combalbert J, Fabre J, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P (1989) Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin-inducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 17: 197–207
Davenport A, Will EJ, Davison AM, Ironside JW (1988) Toxicity of cyclosporin metabolites. Lancet II: 333
Donatsch P, Rickenberger U, Ryffel B, Brouillard JF, Tschopp M, Wullschleger J (1990) Adverse reaction profiles of sandimmune (CSA) metabolites. Transplant Proc 22(3): 1137–1140
Hallmann L (1980) Normalwerte und pathologische Abweichungen. In: Hallmann L (Hrsg) Klinische Chemie und Mikroskopie. Thieme, Stuttgart
Hartmann NR, Jardine I (1986) Mass spectrometric analysis of cyclosporine metabolites. Biomed Environ Mass Spectrom 13: 361–372
Hartmann NR, Trimble LA, Vederas JC, Jardine I (1985) An acid metabolite of cyclosporine. Biochem Biophys Res Commun 133: 964–971
Hashem H, Ventkataramanan R, Burckart GJ, Makowka L, Starzl TE, Fu E, Wong LK (1988) Identification of the aldehydic metabolites. Transplant Proc 20: 176–178
Henricsson S, Lindholm A, Johansson A (1989) Identification of a sulfate conjugate of cyclosporine. Transplant Proc 21: 837–839
Kahan BD (1990) Consensus report of the ciclosporin expert meeting, Hawk's Cay, 1990. Transplant Proc 22(3): 1357–1361
Kohlhaw K, Wonigeit K, Schäfer O, Ringe B, Bunzendahl H, Pichlmayr R (1989) Association of very high blood levels of cyclosporine metabolites with clinical complications after liver transplantation. Transplant Proc 21: 2232–2233
Kronbach T, Fischer W, Meyer UA (1988) Cyclosporine metabolism in human liver: Identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630–635
Kunzendorf U, Brockmöller J, Joachimsen F, Keller F, Walz G, Offermann G (1988) Cyclosporin metabolites and central-nervous-system toxicity. Lancet I: 1223
Leunissen K, Baumann G, Bosman R, Van Hoof JP (1986) Cyclosporin metabolites and nephrotoxicity. Lancet II: 1398
Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB (1990) Cyclosporine toxicity at therapeutic blood levels and cytochrome P450IIIA. Lancet 335: 11–15
Maurer G, Lemaire M (1986) Biotransformation of cyclosporine and distribution in blood. Transplant Proc 18: 25–34
Maurer G, Loosli R, Schreier E, Keller H (1984) Disposition of cyclosporine in several animal species and man- structural elucidation of its metabolites. Drug Metab Dispos 12: 120–126
Ptachcinski RJ, Ventkataramanan R, Burckart GJ (1986) Clinical pharmacokinetics of cyclosporine. Clin Pharmacokin 11: 107–132
Quesniaux VFJ, Schreier MH, Wenger RM, Hiestand PC, Von Regenmortel MHV (1988) Cyclosporine-cyclophilin interaction. Transplant Proc 20: 38–62
Roesel T, Le Grue SJ, Liehr J, Kahan BD (1989) Isolation and in vitro characterization of a novel immunosuppressive cyclosporine metabolite. Transplantation 47: 149–156
Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N (1988) Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplant Proc 20: 330–338
Ryffel B, Foxwell BMJ, Mihatsch MJ, Donatsch P, Maurer G (1988) Biologic significance of cyclosporine metabolites. Transplant Proc 20: 575–584
Scharschmidt BF (1990) Bile formation and cholestasis. In: Zakim D, Boyer TD (eds) Hepatology. Vol. 1, 2nd ed. Saunders, Philadelphia, pp 303–340
Sewing KF, Christians U, Bleck JS, Schottmann R, Strohmeyer SS (1988) Measurement and disposition of cyclosporine and its metabolites. Bibliotheca Cardiol 43: 63–72
Sewing KF, Christians U, Kohlhaw K, Radeke HH, Strohmeyer S, Kownatzki R, Budniak J, Schottmann R, Bleck JS, Almeida VMF, Deters M, Wonigeit K, Pichlmayr R (1990) Biologic activity of ciclosporin metabolites. Transplant Proc 22: 1129–1136
Wadhwa NK, Schroeder TJ, Amadeo JP, Myre SA, Clardy SW, First MR (1987) Cyclosporine drug interactions: a review. Ther Drug Monit 9: 399–406
Wallemacq PE, Lhoëst G, Latinne D, De Bruyere M (1989) Isolation, characterization and in vitro activity of cyclosporin A metabolites. Transplant Proc 21: 906–910
Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R (1990) Cyclosporine monitoring in liver allograft recipients. Two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 22: 1305–1311
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bleck, J.S., Schlitt, H.J., Christians, U. et al. Ciclosporin metabolite pattern in blood and urine of kidney graft patients in relation to liver function. Eur J Clin Pharmacol 40, 565–569 (1991). https://doi.org/10.1007/BF00279971
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00279971